ALNY vs. APLS: A Head-to-Head Stock Comparison

Updated on July 7, 2025

Here’s a clear look at ALNY and APLS, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Overview

ALNY’s market capitalization of 43.28 billion USD is substantially larger than APLS’s 2.29 billion USD, indicating a significant difference in their market valuations.

APLS carries a higher beta at 0.67, indicating it’s more sensitive to market moves, while ALNY (beta: 0.21) exhibits greater stability.

Symbol	ALNY	APLS
Company Name	Alnylam Pharmaceuticals, Inc.	Apellis Pharmaceuticals, Inc.
Country	US	US
Sector	Healthcare	Healthcare
Industry	Biotechnology	Biotechnology
CEO	Yvonne L. Greenstreet	Cedric Francois
Price	331.91 USD	18.26 USD
Market Cap	43.28 billion USD	2.29 billion USD
Beta	0.21	0.67
Exchange	NASDAQ	NASDAQ
IPO Date	June 1, 2004	November 9, 2017
ADR	No	No

Historical Performance

This chart compares the performance of ALNY and APLS by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.

Data is adjusted for dividends and splits.

ALNY vs. APLS: Growth of a $10,000 investment over the past one year.

Profitability

Return on Equity

ALNY

-509.33%

Biotechnology Industry

Max: 72.39%
Q3: -6.30%
Median: -32.82%
Q1: -68.26%
Min: -147.61%

ALNY has a negative Return on Equity of -509.33%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

APLS

-100.06%

Biotechnology Industry

Max: 72.39%
Q3: -6.30%
Median: -32.82%
Q1: -68.26%
Min: -147.61%

APLS has a negative Return on Equity of -100.06%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

ALNY vs. APLS: A comparison of their ROE against the Biotechnology industry benchmark.

Return on Invested Capital

ALNY

-2.79%

Biotechnology Industry

Max: 48.74%
Q3: -10.68%
Median: -31.65%
Q1: -52.92%
Min: -113.69%

ALNY has a negative Return on Invested Capital of -2.79%. This indicates that its operations are failing to generate a profit on the total capital invested, signaling significant inefficiency or value destruction.

APLS

-29.46%

Biotechnology Industry

Max: 48.74%
Q3: -10.68%
Median: -31.65%
Q1: -52.92%
Min: -113.69%

APLS has a negative Return on Invested Capital of -29.46%. This indicates that its operations are failing to generate a profit on the total capital invested, signaling significant inefficiency or value destruction.

ALNY vs. APLS: A comparison of their ROIC against the Biotechnology industry benchmark.

Net Profit Margin

ALNY

-11.49%

Biotechnology Industry

Max: 87.75%
Q3: -5.05%
Median: -103.44%
Q1: -1,032.77%
Min: -2,366.07%

ALNY has a negative Net Profit Margin of -11.49%, indicating the company is operating at a net loss as its expenses exceeded its revenues.

APLS

-28.83%

Biotechnology Industry

Max: 87.75%
Q3: -5.05%
Median: -103.44%
Q1: -1,032.77%
Min: -2,366.07%

APLS has a negative Net Profit Margin of -28.83%, indicating the company is operating at a net loss as its expenses exceeded its revenues.

ALNY vs. APLS: A comparison of their Net Profit Margin against the Biotechnology industry benchmark.

Operating Profit Margin

ALNY

-4.91%

Biotechnology Industry

Max: 87.75%
Q3: -3.28%
Median: -115.26%
Q1: -1,188.86%
Min: -2,943.30%

ALNY has a negative Operating Profit Margin of -4.91%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.

APLS

-24.00%

Biotechnology Industry

Max: 87.75%
Q3: -3.28%
Median: -115.26%
Q1: -1,188.86%
Min: -2,943.30%

APLS has a negative Operating Profit Margin of -24.00%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.

ALNY vs. APLS: A comparison of their Operating Margin against the Biotechnology industry benchmark.

Profitability at a Glance

Symbol	ALNY	APLS
Return on Equity (TTM)	-509.33%	-100.06%
Return on Assets (TTM)	-6.40%	-27.71%
Return on Invested Capital (TTM)	-2.79%	-29.46%
Net Profit Margin (TTM)	-11.49%	-28.83%
Operating Profit Margin (TTM)	-4.91%	-24.00%
Gross Profit Margin (TTM)	86.01%	82.94%

Financial Strength

Current Ratio

ALNY

3.04

Biotechnology Industry

Max: 28.73
Q3: 13.97
Median: 6.31
Q1: 3.60
Min: 0.02

ALNY’s Current Ratio of 3.04 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

APLS

4.08

Biotechnology Industry

Max: 28.73
Q3: 13.97
Median: 6.31
Q1: 3.60
Min: 0.02

APLS’s Current Ratio of 4.08 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.

ALNY vs. APLS: A comparison of their Current Ratio against the Biotechnology industry benchmark.

Debt-to-Equity Ratio

ALNY

11.28

Biotechnology Industry

Max: 0.46
Q3: 0.22
Median: 0.06
Q1: 0.02
Min: 0.00

With a Debt-to-Equity Ratio of 11.28, ALNY operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.

APLS

2.86

Biotechnology Industry

Max: 0.46
Q3: 0.22
Median: 0.06
Q1: 0.02
Min: 0.00

With a Debt-to-Equity Ratio of 2.86, APLS operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.

ALNY vs. APLS: A comparison of their D/E Ratio against the Biotechnology industry benchmark.

Interest Coverage Ratio

ALNY

-0.79

Biotechnology Industry

Max: 108.32
Q3: -0.55
Median: -8.49
Q1: -74.83
Min: -168.36

ALNY has a negative Interest Coverage Ratio of -0.79. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

APLS

-4.19

Biotechnology Industry

Max: 108.32
Q3: -0.55
Median: -8.49
Q1: -74.83
Min: -168.36

APLS has a negative Interest Coverage Ratio of -4.19. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

ALNY vs. APLS: A comparison of their Interest Coverage against the Biotechnology industry benchmark.

Financial Strength at a Glance

Symbol	ALNY	APLS
Current Ratio (TTM)	3.04	4.08
Quick Ratio (TTM)	2.98	3.62
Debt-to-Equity Ratio (TTM)	11.28	2.86
Debt-to-Asset Ratio (TTM)	0.31	0.58
Net Debt-to-EBITDA Ratio (TTM)	-1.85	-0.63
Interest Coverage Ratio (TTM)	-0.79	-4.19

Growth

The following charts compare key year-over-year (YoY) growth metrics for ALNY and APLS. These metrics are based on the companies’ annual financial reports.

Revenue Growth

ALNY vs. APLS: A comparison of their annual year-over-year Revenue Growth.

Earnings Per Share (EPS) Growth

ALNY vs. APLS: A comparison of their annual year-over-year Earnings Per Share (EPS) Growth.

Free Cash Flow Growth

ALNY vs. APLS: A comparison of their annual year-over-year Free Cash Flow Growth.

Dividend

Dividend Yield

ALNY

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ALNY currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

APLS

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

APLS currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

ALNY vs. APLS: A comparison of their Dividend Yield against the Biotechnology industry benchmark.

Dividend Payout Ratio

ALNY

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ALNY has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

APLS

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

APLS has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

ALNY vs. APLS: A comparison of their Payout Ratio against the Biotechnology industry benchmark.

Dividend at a Glance

Symbol	ALNY	APLS
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

Price-to-Earnings Ratio

ALNY

-159.59

Biotechnology Industry

Max: 78.44
Q3: 48.98
Median: 20.50
Q1: 12.64
Min: 2.14

ALNY has a negative P/E Ratio of -159.59. This occurs when a company has negative earnings (a net loss), making the ratio unsuitable for valuation analysis.

APLS

-10.24

Biotechnology Industry

Max: 78.44
Q3: 48.98
Median: 20.50
Q1: 12.64
Min: 2.14

APLS has a negative P/E Ratio of -10.24. This occurs when a company has negative earnings (a net loss), making the ratio unsuitable for valuation analysis.

ALNY vs. APLS: A comparison of their P/E Ratio against the Biotechnology industry benchmark.

Forward P/E to Growth Ratio

ALNY

-43.29

Biotechnology Industry

Max: 2.29
Q3: 1.10
Median: 0.49
Q1: 0.16
Min: 0.02

ALNY has a negative Forward PEG Ratio of -43.29. This typically results from negative earnings or forecasts of declining future earnings, making the ratio not meaningful for valuation.

APLS

0.81

Biotechnology Industry

Max: 2.29
Q3: 1.10
Median: 0.49
Q1: 0.16
Min: 0.02

APLS’s Forward PEG Ratio of 0.81 is within the middle range of its peers in the Biotechnology industry. This suggests a reasonable balance between the stock’s price and its expected growth, aligning with sector valuation norms.

ALNY vs. APLS: A comparison of their Forward PEG Ratio against the Biotechnology industry benchmark.

Price-to-Sales Ratio

ALNY

18.43

Biotechnology Industry

Max: 110.90
Q3: 59.76
Median: 11.33
Q1: 4.45
Min: 0.17

ALNY’s P/S Ratio of 18.43 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

APLS

2.96

Biotechnology Industry

Max: 110.90
Q3: 59.76
Median: 11.33
Q1: 4.45
Min: 0.17

In the lower quartile for the Biotechnology industry, APLS’s P/S Ratio of 2.96 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.

ALNY vs. APLS: A comparison of their P/S Ratio against the Biotechnology industry benchmark.

Price-to-Book Ratio

ALNY

372.86

Biotechnology Industry

Max: 15.78
Q3: 7.44
Median: 3.31
Q1: 1.58
Min: 0.31

The P/B Ratio is often not a primary valuation metric for the Biotechnology industry.

APLS

13.95

Biotechnology Industry

Max: 15.78
Q3: 7.44
Median: 3.31
Q1: 1.58
Min: 0.31

The P/B Ratio is often not a primary valuation metric for the Biotechnology industry.

ALNY vs. APLS: A comparison of their P/B Ratio against the Biotechnology industry benchmark.

Valuation at a Glance

Symbol	ALNY	APLS
Price-to-Earnings Ratio (P/E, TTM)	-159.59	-10.24
Forward PEG Ratio (TTM)	-43.29	0.81
Price-to-Sales Ratio (P/S, TTM)	18.43	2.96
Price-to-Book Ratio (P/B, TTM)	372.86	13.95
Price-to-Free Cash Flow Ratio (P/FCF, TTM)	-574.08	-272.85
EV-to-EBITDA (TTM)	-285.32	-13.67
EV-to-Sales (TTM)	18.55	3.10